Smallpox: clinical features, prevention, and management.
OBJECTIVE
To describe a general overview of smallpox, clinical presentation, diagnosis, adverse events, and management of both pre- and postexposure vaccination.


METHODS
Literature was identified by search of MEDLINE (1966-June 2003) and International Pharmaceutical Abstracts (1966-May 2003) databases using the key terms smallpox, bioterrorism, biological warfare, and smallpox vaccine.


METHODS
Articles identified from data sources were evaluated, and relevant information was included in this review.


RESULTS
Smallpox is spread by human-to-human contact with an infected host and therefore can be contagious. The mortality rate for smallpox is approximately 30%. While the disease was completely eradicated by 1980 with successful use of smallpox vaccine, concern has been raised that smallpox may emerge as a tool of bioterrorism. This concern, combined with the reality of current smallpox vaccination programs in the military and selected civilian populations, mandates a clear understanding of vaccination-related adverse events and contraindications by all healthcare professionals. The vaccine may cause moderate to severe adverse events such as eczema vaccinatum, progressive vaccinia, and generalized vaccinia.


CONCLUSIONS
The balance between the risks and benefits of mass vaccination in prevention of an epidemic is not clear. The Centers for Disease Control and Prevention has established a guideline for appropriate use of smallpox vaccine in the civilian population.
Guharoy
Roy
R
Section of Clinical Pharmacology, SUNY-Upstate Medical University, Syracuse, NY, USA. GuharoyR@Upstate.edu
Panzik
Robert
R
Noviasky
John A
JA
Krenzelok
Edward P
EP
Blair
Donald C
DC
D000998:Antiviral Agents / Q000627:therapeutic use*; D023482:Bioterrorism; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D012899:Smallpox / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D012900:Smallpox Vaccine / Q000009:adverse effects*
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D012900:Smallpox Vaccine; D003596:Cytosine; D000077404:Cidofovir